Venrock Healthcare Capital Partners

Funding rounds backed by Venrock Healthcare Capital Partners.

Export CSV
Funding disclosed in full
$645M
Median round
$220M
Rounds in calculation
3
3 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DBiotechUnited Kingdom
9 participantsAmerican Cancer Society BrightEdgeAvego BioScience CapitalFidelity Management & Research CompanyForbionHBM HealthcarePfizerRA Capital ManagementSofinnova PartnersVenrock Healthcare Capital Partners
Korsana Biosciences

Develops novel therapies to reduce the burden of neurodegenerative diseases

$175MSeries ABiotechUnited States
8 participantsFairmountForesite CapitalJanus Henderson InvestorsJ.P. Morgan Life Sciences Private CapitalSanofi VenturesTCGXVenrock Healthcare Capital PartnersWellington Management
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries BBiotechUnited States
17 participantsAdage Capital Partners L.P.ARCH Venture PartnersBlue Owl Healthcare OpportunitiesBoxer CapitalFairmountFarallon Capital ManagementFidelity Management & Research CompanyInc.InvusLogos CapitalMoore Strategic VenturesOrbiMedPoint72TCGXT. Rowe Price Investment ManagementVenrock Healthcare Capital PartnersWoodline Partners LP